908 Devices (MASS) Leerink Global Healthcare Conference 2026 summary

Market drivers and macro environment

• Demand is driven by illicit drug crises, toxic industrial chemicals, and global unrest, with conflicts like Ukraine and Middle East tensions increasing customer prioritization for modernization and preparedness.

• NATO countries are increasing defense spending targets to 5% of GDP by 2035, supporting a rising tide in customer demand.

• International revenues grew from 25% to 27% of total, with significant opportunities for further expansion, especially in Europe and APAC.

• Distribution channels are used internationally, resulting in lower ASPs but scalable growth and similar bottom-line contributions.

• Secular trends and record funding levels are creating favorable conditions for technology adoption in forensics and chemical detection.

Financial performance and outlook

• Achieved 21% revenue growth in Q4, exceeding guidance despite government shutdown risks.

• State and local customers accounted for 43% of annual revenue, supported by grant funding cycles.

• Guidance for 2026 targets 15%-20% annual growth, with Q1 expected to be slower due to product restocking and typical seasonality.

• Adjusted EBITDA turned positive in Q4, with a path to full-year profitability by 2027 as growth and margin improvements continue.

• Gross margin is expected to expand by about 100 basis points, driven by insourcing, product mix, and recurring revenue growth.

Product innovation and pipeline

• Next-gen MX908 handheld mass spectrometer will be announced later this year, targeting both replacement and expansion opportunities.

• VipIR and XplorIR products are gaining traction, with over 40 and 150 installs respectively, and are expected to drive growth in state, local, and international markets.

• AVCAD OEM program is expected to contribute $2M-$3M in 2026, ramping to $10M+ annually over five to seven years.

• Team Leader software and recurring revenue streams are being developed to increase predictability and customer value.

• Continued investment in new product development and international sales resources is prioritized to capture market expansion.